NCT02725437View on ClinicalTrials.gov

Clostridium Difficile Vaccine Safety, Tolerability, and Immunogenicity Study in Japanese Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

February 28, 2017

Study Completion Date

February 28, 2017

Conditions
Clostridium Difficile Associated Disease
Interventions
BIOLOGICAL

Clostridium difficile Vaccine

0.5 mL intramuscular injection

BIOLOGICAL

Placebo

0.5 mL intramuscular injection

Trial Locations (2)

130-0004

SOUSEIKAI Sumida Hospital (formerly Medical Co. LTA Sumida Hospital), Sumida-ku

812-0025

SOUSEIKAI PS Clinic (formerly Medical Co. LTA PS Clinic), Fukuoka

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY